Insiders Trades
DocMorris AG Stock: price and insider trades · Switzerland
No insider purchase over the last 90 days. The latest was filed 29 Jun 2026.
DocMorris AG: what insiders have been doing
DocMorris AG, founded in 1993, is a Healthcare & Pharma company based in Frauenfeld, Switzerland. Its directors and officers file their transactions with SIX SER. From 18 October 2025 to 18 October 2026, the disclosure feed for DocMorris AG logged 16 filings by 4 insiders.
Every open-market trade in the period is a purchase: 16 purchases worth €1.4M, from 4 insiders, and not a single sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €218k, published on 22 April 2026. On the buying side, the filings list 4 senior executives among the declarants.
With 16 filings in twelve months, the company is more active than the median of 9 filings across the 178 companies we follow on the same exchange. The full history, which starts in 2023, counts 69 purchases against 15 sales.
The data flag 14 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 110 days ago, on 29 June 2026. Half of the filings or more reach the SIX SER feed on the day of the trade. This delay matters because a trade only becomes useful information once it is public.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SIX SER. They describe what insiders did and are not a recommendation.
Insider Decl.
84
Thresholds
n/a
Buy Volume
€6M
69 ops. · all time
Sell Volume
€2M
15 ops. · all time
Who traded when
BuySaleAnonymous (Non-executive member of the board of directors)24 buys12 sales
Anonymous (Executive member of the board of directors / member of senior management)27 buys2 sales
Anonymous (a non-executive member of the board of directors)3 buys
Anonymous (an executive member of the board of directors / member of senior management)1 buy
Analyst consensus: bullish or bearish?
Analysts rate DocMorris AG Buy (bullish), based on 8 analysts. Average price target: CHF 11.41.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,091 of 24,148 companies
14.9
score / 100
Value12
Quality18
FCF yld-15%
Earn yld-17%
EV/EBITDA·
ROE-30%
Gross mgn22%
Net mgn-12%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CHF 13.87
Analyst consensus
8 analystsBuy
CHF 9.60Target CHF 11.41(-18%)CHF 14.50
Income statement
RevenueCHF 1.1B
Gross profitCHF 250M22% margin
EBITDA-CHF 57.5M-5% margin
Net income-CHF 134.4M-10.7% margin
Valuation
PER (forward)-15.5x
P/Book1.9x
Beta1.78
Balance sheet & cash
Market capCHF 707.1M
Total debtCHF 288.6M
Free Cash Flow-CHF 115.9M
Debt / Equity74%
Profitability & ownership
ROE-30.0%
ROA-6.4%
% insiders36.4%
% institutions21.9%
Last declaration on 29 June 2026
Declarations84 total
6,688 shares@ CHF 9.030.021% mcap13.3% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q6T00046
Canonical exit: 27 Sept 2026 (T+90)
6,688 shares@ CHF 9.02740.021% mcap1.3% of flowISIN CH0042615283SIX:T1Q6T00046
Canonical exit: 27 Sept 2026 (T+90)
▲
Anonymous (an executive member of the board of directors / member of senior management)
1,321 shares@ CHF 6.61100.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q5M00027
Canonical exit: 20 Aug 2026 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
1,321 shares@ CHF 6.6050.4% of flowISIN CH0042615283SIX:T1Q5M00027
Canonical exit: 20 Aug 2026 (T+90)
26,700 shares@ CHF 7.5044.4% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4M00053
Canonical exit: 21 Jul 2026 (T+90)
26,700 shares@ CHF 7.49794.2% of flowISIN CH0042615283SIX:T1Q4M00053
Canonical exit: 21 Jul 2026 (T+90)
28,000 shares@ CHF 6.7942.2% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4K00024
Canonical exit: 19 Jul 2026 (T+90)
28,000 shares@ CHF 6.78754.0% of flowISIN CH0042615283SIX:T1Q4K00024
Canonical exit: 19 Jul 2026 (T+90)
160 shares@ CHF 3.96190.0% of flowISIN CH0042615283SIX:T1Q3O000A8
Canonical exit: 22 Jun 2026 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
2,000 shares@ CHF 4.600.5% of flowISIN CH0042615283SIX:T1Q3J00044
Canonical exit: 17 Jun 2026 (T+90)
25,000 shares@ CHF 4.262.2% of flowISIN CH0042615283SIX:T1Q3J00010
Canonical exit: 17 Jun 2026 (T+90)
19,800 shares@ CHF 4.101.7% of flowISIN CH0042615283SIX:T1Q3J00028
Canonical exit: 17 Jun 2026 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
4,269 shares@ CHF 4.05950.9% of flowISIN CH0042615283SIX:T1Q3J00069
Canonical exit: 17 Jun 2026 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
1,124 shares@ CHF 5.980.3% of flowISIN CH0042615283SIX:T1PCG00060
Canonical exit: 16 Mar 2026 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
1,250 shares@ CHF 4.800.3% of flowISIN CH0042615283SIX:T1PBL00047
Canonical exit: 19 Feb 2026 (T+90)
20,000 shares@ CHF 5.44272.3% of flowISIN CH0042615283SIX:T1PAN00011
Canonical exit: 21 Jan 2026 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
3,400 shares@ CHF 5.931.0% of flowISIN CH0042615283SIX:T1P9Q00013
Canonical exit: 25 Dec 2025 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
1,754 shares@ CHF 5.69180.5% of flowISIN CH0042615283SIX:T1P9Q00021
Canonical exit: 25 Dec 2025 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
2,500 shares@ CHF 5.89350.7% of flowISIN CH0042615283SIX:T1P9P00049
Canonical exit: 24 Dec 2025 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
1,550 shares@ CHF 6.0850.5% of flowISIN CH0042615283SIX:T1P9G00048
Canonical exit: 15 Dec 2025 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
1,950 shares@ CHF 6.0850.6% of flowISIN CH0042615283SIX:T1P9B00023
Canonical exit: 10 Dec 2025 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
5,300 shares@ CHF 6.361.7% of flowISIN CH0042615283SIX:T1P6N00032
Canonical exit: 21 Sept 2025 (T+90)
7,000 shares@ CHF 6.9431.0% of flowISIN CH0042615283SIX:T1P6A00013
Canonical exit: 8 Sept 2025 (T+90)
▲
Anonymous (Executive member of the board of directors / member of senior management)
2,500 shares@ CHF 7.741.0% of flowISIN CH0042615283SIX:T1P6500021
Canonical exit: 3 Sept 2025 (T+90)
6,000 shares@ CHF 8.60781.1% of flowISIN CH0042615283SIX:T1P5S00033
Canonical exit: 26 Aug 2025 (T+90)
25 of 84 declarations
About DocMorris AG
DocMorris AG is a European digital health and online pharmacy group listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland. The company was founded in 1993 and developed from a pharmaceutical distribution background into a digital platform focused on access to medicines, healthcare advice, and related services. Its registered office and business management headquarters are in Frauenfeld, Switzerland, reflecting its status as a Swiss-incorporated company.
The group operates several e-commerce pharmacies for medical and pharmaceutical products and also provides professional health care services. Its product and service offering includes prescription medicines, over-the-counter drugs, and consumer health categories such as beauty and personal care. Strategically, DocMorris is positioning itself as a broader digital health ecosystem rather than a traditional online retailer. Its stated vision is to connect patients, doctors, pharmacies, and health insurers on a single platform, thereby expanding the company’s role beyond transactional pharmacy sales into recurring digital health services.
Read moreShow less
From a competitive standpoint, DocMorris is one of the better-known pure-play online pharmacy operators in Europe. It combines a strong consumer brand with a multi-country operating footprint across Germany, the Netherlands, Spain, France, Portugal, and Switzerland. This geographic spread supports diversification, but it also exposes the company to country-specific regulation, reimbursement frameworks, and the pace of digital adoption in pharmacy and healthcare. For equity investors, that means the company’s growth profile depends not only on customer acquisition and retention, but also on regulatory execution and operational scalability.
Recent developments point to a clear strategic reset toward profitability and technology-led differentiation. In 2025, DocMorris continued to emphasize qualitative growth and operational efficiency, while in 2026 it announced a partnership with Google to accelerate an AI-powered health platform. Management highlighted four focus areas: an AI health companion, an AI-enhanced online pharmacy, operational efficiency, and cloud/data security. The group also announced the closure of its Ludwigshafen site by the end of June 2026, with logistics to be integrated into its highly automated Heerlen facility. Management reaffirmed its target of reaching EBITDA break-even during 2026 and free cash flow break-even during 2027. Overall, DocMorris remains a growth-oriented healthcare technology and pharmacy platform listed in Switzerland, with improving strategic clarity but execution still central to the investment case.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
